Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Early detection of myeloproliferative neoplasms in a Danish general population study

Leukemia volume 35, pages 2706–2709 (2021)Cite this article

Subjects

The chronic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are characterized by elevated blood cell counts and distinct histological bone marrow changes. We [1] and others [2] have raised concerns about a considerable underdiagnosis of MPN in the general population. As the risk of thrombohemorrhagic complications [3, 4] and associated morbidities [4,5,6,7] are present years before time of MPN diagnosis, we find a rationale for diagnosing MPN in earlier disease stages to prevent development of these complications and disorders. Another perspective is the possibility of diminishing MPN disease progression by early upfront treatment with immune modulating treatments such as interferon [8, 9].

From the Danish General Suburban Population Study in Region Zealand (GESUS) from 2010 to 2013 [10], we established two screening strategies: (1) a baseline mutation screening strategy only based on presence of either JAK2V617F or calreticulin type 1/2 mutations (CALR) and (2) an elevated blood count screening strategy with detection of JAK2V617F or CALR in citizens with long-term elevation of blood cell counts. Study protocols were approved by the Regional Committee on Health Research Ethics (SJ-452, SJ-114) and the Danish Data Protection Agency (REG-50-2015) and complied with the Declaration of Helsinki and General Data Protection Rules. Written consent from all participants was obtained. Digital droplet PCR was used to detect and quantify the JAK2V617F and CALR mutant allele burden. Long-term elevation of blood cell counts was defined as hemoglobin >15.3 g/dL (female)/>16.9 g/dL (male); hematocrit >0.46 (female)/>0.50 (male); leukocytes >8.8 × 109/L; or platelets >390 × 109/L in GESUS (baseline) and in a follow-up blood test in 2016–2017 (Supplementary Fig. S1). Participants were offered medical investigation including bone marrow examination to detect possible/early or overt MPN. Of 29 invited, 25 mutation-positive citizens consented to participate from the baseline mutation screening strategy of which five declined bone marrow examination. The only measures taken into account in the selection of the 29 individuals were mutation type and allele burden to ensure that both JAK2V617F and CALR positives were represented as well as allele burdens both below and above 1%. Among 373 randomly selected citizens with long-term elevation of blood cell counts, we detected 32 to be mutation positive (Supplementary Fig. S1). Twenty-four consented to participate of which three declined bone marrow examination. Thus, in total, 41 (20 and 21 in each screening group, respectively) participants underwent bone marrow examination. Bone marrow examinations (biopsy, aspiration, and peripheral blood smear) were independently reviewed by two hematopathologists in a blinded setup where only data regarding patient age and gender were accessible. The findings were classified as either no MPN, early/possible MPN, or overt MPN based on Madelung et al. [11] and WHO classification 2016 [12]. For details, see Supplementary Information.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 2019;134:469–79. http://www.ncbi.nlm.nih.gov/pubmed/31217187.

  2. Barbui T, Thiele J, Gisslinger H, Carobbio A, Vannucchi AM, Tefferi A. Diagnostic impact of the 2016 revised who criteria for polycythemia vera. Am J Hematol. 2017;92:417–9. http://www.ncbi.nlm.nih.gov/pubmed/28196400.

  3. Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J, et al. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med. 2015;26:344–7. https://linkinghub.elsevier.com/retrieve/pii/S0953620515000928.

  4. Sørensen AL, Hasselbalch HC. Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2016;41:27–35. http://www.ncbi.nlm.nih.gov/pubmed/26718091.

  5. Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95:1216–20. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2895049&tool=pmcentrez&rendertype=abstract.

  6. Pettersson H, Knutsen H, Holmberg E, Andréasson B. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol. 2015;94:152–6. http://www.ncbi.nlm.nih.gov/pubmed/25039361.

  7. Fallah M, Kharazmi E, Sundquist J, Hemminki K. Higher risk of primary cancers after polycythaemia vera and vice versa. Br J Haematol. 2011;153:283–5. http://www.ncbi.nlm.nih.gov/pubmed/21275965.

  8. Craver B, El Alaoui K, Scherber R, Fleischman A. The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers. 2018;10:104. http://www.ncbi.nlm.nih.gov/pubmed/29614027.

  9. Hasselbalch HC. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?. Leuk Res. 2009;33:11–8. http://www.sciencedirect.com/science/article/pii/S0145212608002786.

  10. Bergholdt HKM, Bathum L, Kvetny J, Rasmussen DB, Moldow B, Hoeg T, et al. Study design, participation and characteristics of the Danish General Suburban Population Study. Dan Med J. 2013;60:A4693.

  11. Madelung AB, Bondo H, Stamp I, Loevgreen P, Nielsen SL, Falensteen A, et al. World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations—the Danish experience. Am J Hematol. 2013;88:1012–6. http://www.ncbi.nlm.nih.gov/pubmed/23897670.

  12. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2017.

  13. Ye X-P, Bao S, Gao H-M, Guo Y, Wei Y-P. A case of myeloproliferative neoplasm with a normal complete blood cell count: a novel problem of the JAK2 era. Oncol Lett. 2016;11:2134–6. https://www.spandidos-publications.com/10.3892/ol.2016.4192.

Download references

Acknowledgements

This work was supported by grants from Region Zealand Research Foundation; Manufacturer Einar Willumsens Memorial Foundation; Anders Hasselbalch’s Foundation Fighting Leukemia; Carpenter Joergen Holm and Wife Elisa F. Hansen’s Memorial Foundation; Else and Mogens Wedell-Wedellborgs Foundation; the Hoejmosegaard Scholarship; Eva and Henry Fraenkels Memorial Foundation; Dagmar Marshalls Foundation; Candys Foundation; A.V. Lykfeldt and Wife’s Scholarship; and Aase and Ejnar Danielsen’s Foundation. The Danish General Suburban Population Study was funded by the Region Zealand Research Foundation; Naestved Hospital Foundation; Naestved Municipality; Johan and Lise Boserup Foundation; TrygFonden; Johannes Fog’s Foundation; Region Zealand; Naestved Hospital; The National Board of Health; and the Local Government Denmark Foundation. The sponsors are public or nonprofit organizations that support science in general. They had no role in gathering, analysing, or interpreting the data.

Author information

Author notes

  1. These authors contributed equally: H.C. Hasselbalch, C. Ellervik

Authors and Affiliations

  1. Department of Hematology, Zealand University Hospital, Roskilde, Denmark

    S. Cordua, L. Kjaer, V. Skov & H. C. Hasselbalch

  2. Department of Pathology, Zealand University Hospital, Roskilde, Denmark

    N. Pallisgaard, M. Kefala & L. M. R. Gjerdrum

  3. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    L. M. R. Gjerdrum & C. Ellervik

  4. Department of Data and Data Support, Region Zealand, Sorø, Denmark

    C. Ellervik

  5. Department of Laboratory Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA

    C. Ellervik

Authors
  1. S. Cordua
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Kjaer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Skov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Pallisgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Kefala
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. M. R. Gjerdrum
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. C. Hasselbalch
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Ellervik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Cordua.

Ethics declarations

Conflict of interest

NP: Novartis: research support, honorarium, travel grant; InCyte: research support. LMRG: NanoString: research funding. HCH: Novartis: research grant; AOP Orphan: advisory board. SC, LK, VS, MK, and CE declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cordua, S., Kjaer, L., Skov, V. et al. Early detection of myeloproliferative neoplasms in a Danish general population study. Leukemia 35, 2706–2709 (2021). https://doi.org/10.1038/s41375-021-01159-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-021-01159-8

This article is cited by

Search

Advanced search

Quick links